Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of MRUS is 97 and suggests 8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation sug
Buy
Sell